肾性高血压治疗的药物疗效与经济学分析  

Drug efficacy and economics analysis of 4 regimens for renal hypertension

作　　者：马葵芬[1] 邵黎虹[1] 张幸国[1] 

机构地区：[1]浙江大学医学院附属第一医院,浙江杭州310003

出　　处：《中国医院药学杂志》2012年第1期40-43,共4页Chinese Journal of Hospital Pharmacy

基　　金：浙江省医学会临床科研资金项目(编号:2009ZYC9)

摘　　要：目的:探讨临床常用肾性高血压药物的临床效果和经济效果。方法:收集门诊肾性高血压患者服用(缬沙坦胶囊,氯沙坦钾片,氨氯地平片,贝那普利片)的病例资料,运用药物经济学中的成本-效果分析等方法对肾性高血压疾病的不同药物治疗方案进行分析评论。结果:4种给药方案对降压作用的成本效果比分别为478,597,570,410;蛋白尿改善作用的成本效果比值分别为541,538,674,770;血肌酐改善作用的成本效果比值分别为478,672,570,616。结论:4种给药方案对不同疗效指标最佳给药方案的经济学分析结果略有差异,综合考虑,本研究中最佳的给药方案为缬沙坦组。OBJECTIVE To discuss the clinical efficacy and economic effects of 4 regimens for renal hypertension. METHODS The clinical data of renal hypertension patients administrated with valsartan capsules, losartan potassium tablets, amlodipine besylate tablets, benazepril hydroehloride tablets were collected. Cost-effectiveness analysis and other pharmacoeconomical methods were applied for economics analysis in renal hypertension patients. RESULTS Cost-effectiveness of 4 regimens on antihypertensive effects was 478, 597, 570 and 410 respectively. Cost-effectiveness on improvement of protein-uria was 541, 538, 674 and 770 respectively. Cost-effectiveness on improvement of serum creatinine was 478, 672, 570 and 616. CONCLUSION Economic analysis outcome of 4 regimens on different measurements was slightly different. And considering the comprehensive results, the best regimen for renal hypertension was valsartan group in the present study.

关 键 词：药物经济学 肾性高血压 成本效果分析 

分 类 号：R969[医药卫生—药理学]